Cell Culture – News and Features

MultiCell has granted Eisai a 5-year nonexclusive license to use its Fa2N-4 cells line and MFE™ culture media at Eisai's Tsukuba Research Laboratories.

AVEO Pharmaceuticals has created invasive human tumors that develop over time in mice from primary human breast tissue.

CombinatoRx shows data from its first biologic/small molecule High Throughput Screening effort identifying drug classes that synergistically enhance the activity of the oncology-relevant cytokine TNF-related apoptosis.

ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO™.

Invitrogen will test protein-production techniques and cell-development technology developed by Viropro.

ProBioGen to develop a biopharmaceutical cell line for high-level production of one of the lead candidates in Affitech’s oncology therapeutic antibody pipeline.

Re-examination was initiated by Foundation for Taxpayer and Consumer Rights and Public Patent Foundation.

U-M scientists see great promise in cardiac tissue engineering, but hurdles remain before lab-grown muscle is ready for patients

Kinase drug discovery program will utilize invitrogen’s SelectScreen™ platform

The project is entitled “Characterization of New Human Embryonic Stem Cell Lines and the Differentiation into Retinal Progenitor Cell”.